Inhibrx Biosciences, Inc. INBX Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$130.19M-107% | -$140.06M-108% | -$107.22M-107% | -$115.83M-107% | $1.77B+753% | ||
| $2.35M-9.8% | $2.48M+8.7% | $2.61M+37.8% | $2.79M+93.9% | $2.6M+107% | ||
| $11.34M-79.2% | $11.14M-81.0% | $11.38M-81.6% | $11.17M-83.0% | $54.57M— | ||
| $2.64M— | $2.44M— | —— | —— | —— | ||
| —— | —— | —— | —— | -$15K— | ||
| -$130K— | -$3.3M— | —— | —— | —— | ||
| -$17.43M-157% | -$4.36M-112% | -$2.93M-105% | $4.62M-91.4% | $30.73M— | ||
| $28K-98.8% | $0-100% | $119K-96.7% | $97K-97.3% | $2.25M— | ||
| -$1.97M-82.0% | -$1.6M-13.3% | -$1.13M+38.0% | -$944K+51.8% | -$1.08M— | ||
| -$28K+97.6% | -$20K+96.5% | $543K— | -$222K— | -$1.16M— | ||
| -$131.93M+21.1% | -$129.79M+33.2% | -$143.39M+30.9% | -$139.85M+39.6% | -$167.25M— | ||
| —— | —— | —— | —— | $1.5M— | ||
| —— | —— | —— | —— | -$1.5M— | ||
| $2.08M— | $1.61M— | —— | —— | —— | ||
| $77.07M— | $101.45M— | —— | —— | —— | ||
| —— | —— | —— | —— | -$35.96M— | ||
| $10.38M— | $8.9M— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $2.64M— | $2.44M— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| -$1.97M-82.0% | -$1.6M-13.3% | -$1.13M+38.0% | -$944K+51.8% | -$1.08M— | ||
| -$28K+97.6% | -$20K+96.5% | $543K— | -$222K— | -$1.16M— | ||
| $393K+106% | -$1.4M+53.1% | -$3.58M— | -$7.38M— | -$6.07M— | ||
| —— | $1.8M-5.0% | $1.83M-2.0% | $1.85M+1.0% | $1.87M+4.2% | ||
| —— | —— | —— | —— | —— | ||
| —— | $0-100% | $499.7M-66.7% | $999.4M0.0% | $1.5B+200% | ||
| —— | —— | —— | —— | —— | ||
| —— | $125K— | $93.75K— | $62.5K— | $31.25K— | ||
| -$1.97M-82.0% | -$1.6M-13.3% | -$1.13M+38.0% | -$944K+51.8% | -$1.08M— | ||
| —— | $1.72M— | $1.29M— | $860K— | $430K— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | $99.97M— | ||
| —— | $0— | $6.3M— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| -$131.94M+21.8% | -$129.83M+34.1% | -$143.44M+32.8% | -$140.13M+41.1% | -$168.75M— | ||
| -$131.94M+21.8% | -$129.83M+34.1% | -$143.44M+32.8% | -$140.13M+41.1% | -$168.75M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Inhibrx Biosciences, Inc. generate?
- Inhibrx Biosciences, Inc. (INBX) generated -$131.9M in operating cash flow over the trailing twelve months.
- What is Inhibrx Biosciences, Inc.'s free cash flow?
- After $47.0K of capital expenditures, Inhibrx Biosciences, Inc.'s free cash flow was -$131.9M over the trailing twelve months, up 21.8% year over year.
- Where does Inhibrx Biosciences, Inc.'s cash flow data come from?
- Every line is extracted from Inhibrx Biosciences, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
